Community-acquired pneumonia in HIV-infected individuals

Current Infectious Disease Reports

Volumn 16, Issue 3, 2014, Pages

  Brown, James ^a   Lipman, Marc ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

HIV infection; Immunization; Influenza; Pneumococcal disease; Pneumonia; Smoking

Indexed keywords

ARTICLE; BACTERIAL PNEUMONIA; CD4 LYMPHOCYTE COUNT; COMMUNITY ACQUIRED PNEUMONIA; CORONAVIRUS; DIFFERENTIAL DIAGNOSIS; DRUG USE; HIV TEST; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; KIDNEY DISEASE; PATHOGENESIS; PNEUMOCOCCAL INFECTION; PNEUMOCYSTIS JIROVECI; POPULATION; RESPIRATORY VIRUS; SMOKING; SMOKING CESSATION; STREPTOCOCCUS PNEUMONIAE;

EID: 84898601334     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-014-0397-x     Document Type: Article

References (78)

1. Morris A, Crothers K, Beck JM, Huang L, Huang L. American Thoracic Society Committee on HIV Pulmonary Disease. An official ATS workshop report: emerging issues and current controversies in HIV-associated pulmonary diseases. Proc Am Thorac Soc. 2011;8:17-26.
2. Feldman C, Anderson R. HIV-associated bacterial pneumonia. Clin Chest Med. 2013;34:205-16.
3. Benito N, Moreno A, Miro JM, Torres A. Pulmonary infections in HIV-infected patients: an update in the 21st century. Eur Respir J. 2012;39:730-45.
4. Schwarcz L, Chen MJ, Vittinghoff E, Hsu L, Schwarcz S. Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance. AIDS. 2013;27:597-605. Declining incidences of opportunistic infections based on US AIDS surveillance data.
5. Kim JH, Psevdos Jr G, Gonzalez E, Singh S, Kilayko MC, Sharp V. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART). Infection. 2013;41:545-51. Single institution study documenting changes in mortality following availability of ART.
6. Gingo MR, Balasubramani GK, Kingsley L, Rinaldo Jr CR, Alden CB, Detels R, et al. The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts. PLoS One. 2013;8(3):e58812. Major review of data from the MACS and WHIS cohorts documenting changes in incidence.
7. Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez-Barradas MC, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183:388-95. Important review of current evidence regarding pulmonary disease in HIV-infected individuals based on data from the Veterans Aging Cohort Study virtual cohort.
8. Søgaard OS, Reekie J, Ristola M, Jevtovic D, Karpov I, Beniowski M, et al. Severe bacterial non-AIDS infections in HIV-positive persons: incidence rates and risk factors. J Infect. 2013;66:439-46. Important data from the large EuroSIDA cohort.
9. Lee KY, Ho CC, Ji DD, Lee CM, Tsai MS, Cheng AC, et al. Etiology of pulmonary complications of human immunodeficiency virus-1-infected patients in Taiwan in the era of combination antiretroviral therapy: a prospective observational study. J Microbiol Immunol Infect. 2012;46:433-40.
10. Nunes MC, von Gottberg A, de Gouveia L, Cohen C, Kuwanda L, Karstaedt AS, et al. Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program. PLoS One. 2011;6:e27929.
11. Bénard A, Mercié P, Alioum A, Bonnet F, Lazaro E, Dupon M, et al. Groupe d'Epidémiologie Clinique du Sida en Aquitaine. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007. PLoS One. 2010;5:e8896. Data from French prospective cohort, in particular examining the effect of smoking cessation.
12. Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, Dutta R, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol. 2011;6:442-65.
13. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med. 2000;132:182-90.
14. Siemieniuk RA, Gregson DB, Gill MJ. The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis. 2011;11:314. Important study of the epidemiology of invasive pneumococcal disease amongst HIV-infected people in Canada.
15. Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, Miró JM, et al. INSIGHT-ESPRIT Study Group. Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT). HIV Med. 2011;12:219-27.
16. Shiri T, Auranen K, Nunes MC, Adrian PV, van Niekerk N, de Gouveia L, et al. Dynamics of pneumococcal transmission in vaccine-naive children and their HIV-infected or HIV-uninfected mothers during the first 2 years of life. Am J Epidemiol. 2013;178:1629-37. Confirmation of child to mother transmission of pneumococcal strains in South Africa.
17. Mussini C, Galli L, Lepri AC, De Luca A, Antinori A, Libertone R, et al. ICONA Foundation Study Group. Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort. J Acquir Immune Defic Syndr. 2013;63:339-45. Data from prospective cohort examining risk factors for pneumococcal disease.
18. Gordin FM, Roediger MP, Girard PM, Lundgren JD, Miro JM, Palfreeman A, et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med. 2008;178:640-6. Exploration of risk factors for pneumonia based on data from the SMART randomised controlled trial.
19. Steenhoff AP, Josephs JS, Rutstein RM, Gebo KA, Siberry GK, Gaur AH, et al. Incidence of and risk factors for community acquired pneumonia in US HIV-infected children, 2000-2005. AIDS. 2011;25:717-20.
20. Troeman DP, Postma DF, van Werkoven CH, Oosterheert JJ. The immunomodulatory effects of statins in community-acquired pneumonia: a systematic review. J Infect. 2013;67:93-101.
21. Janssen NE, van Lelyveld SF, Hoepelman AI, Gras L, Groenwold RH, Oosterheert JJ. The effect of statin therapy on pneumonia in an HIV-infected population in the Netherlands. J Infect. 2013;67:238-41.
22. Health Protection Agency. HIV in the United Kingdom: 2012 report. London: Health Protection Services, Colindale; 2012.
23. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data - United States and 6 U.S. dependent areas - 2010. HIV Surveillance Supplemental Report, vol 17, number 3 (part A).
24. Staveteig S, Wang S, Head SK, Bradley SE, Nybro E. Demographic patterns of HIV testing uptake in sub-Saharan Africa. DHS Comparative Reports No. 30. Calverton: ICF International; 2013.
25. Damery S, Nichols L, Holder R, Ryan R, Wilson S, Warmington S, et al. Assessing the predictive value of HIV indicator conditions in general practice: a case-control study using the THIN database. Br J Gen Pract. 2013;63:e370-7. Analysis from the THIN database of primary care records comparing records of 939 cases of HIV infection with 2576 controls demonstrating importance of HIV indicator conditions in primary care.
26. Yin Z, Rice BD, Waight P, Miller E, George R, Brown AE, et al. Invasive pneumococcal disease among HIV-positive individuals, 2000-2009. AIDS. 2012;26:87-94. Analysis of UK national data on invasive pneumococcal disease amongst HIV-infected individuals including coverage by PCV-13 serotypes.
27. Collini P, Noursadeghi M, Sabroe I, Miller RF, Dockrell DH. Monocyte and macrophage dysfunction as a cause of HIV-1 induced dysfunction of innate immunity. Curr Mol Med. 2010;10:727-40.
28. Jambo KC, Sepako E, Fullerton DG, Mzinza D, Glennie S, Wright AK, et al. Bronchoalveolar CD4+ T cell responses to respiratory antigens are impaired in HIV-infected adults. Thorax. 2011;66:375-82.
29. Glennie SJ, Sepako E, Mzinza D, Harawa V, Miles DJ, Jambo KC, et al. Impaired CD4 T cell memory response to Streptococcus pneumoniae precedes CD4 T cell depletion in HIV-infected Malawian adults. PLoS One. 2011;6:e25610. Data elucidating the mechanism for increased rates of pneumococcal disease.
30. Miller E, Bhardwaj N. Dendritic cell dysregulation during HIV-1 infection. Immunol Rev. 2013;254:170-89.
31. Pritschet K, Donhauser N, Schuster P, Ries M, Haupt S, Kittan NA, et al. CD4- and dynamin-dependent endocytosis of HIV-1 into plasmacytoid dendritic cells. Virology. 2012;423:152-64.
32. Gohil SK, Heo M, Schoenbaum EE, Celentano D, Pirofski LA. CD8+ T cells and risk for bacterial pneumonia and all-cause mortality among HIV-infected women. J Acquir Immune Defic Syndr. 2012;60:191-8. Novel data suggesting the importance of CD8+ T cells.
33. Iwai S, Fei M, Huang D, Fong S, Subramanian A, Grieco K, et al. Oral and airway microbiota in HIV-infected pneumonia patients. J Clin Microbiol. 2012;50:2995-3002.
34. Jordano Q, Falcó V, Almirante B, Planes AM, del Valle O, Ribera E, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis. 2004;38(11):1623-8.
35. Gill CJ, Mwanakasale V, Fox MP, Chilengi R, Tembo M, Nsofwa M, et al. Impact of human immunodeficiency virus infection on Streptococcus pneumoniae colonization and seroepidemiology among Zambian women. J Infect Dis. 2008;197:1000-5.
36. Lo YC, Lauderdale TL, Chang SY, Hsiao CF, Hung CC, Chang SC. Streptococcus pneumoniae colonization among patients with human immunodeficiency virus-1 who had received 23-valent polysaccharide pneumococcal vaccine. J Microbiol Immunol Infect. 2009;42:234-42.
37. Öbrink-Hansen K, Søgaard OS, Harboe ZB, Schønheyder HC. Risk factors for pneumococcal nasopharyngeal colonization before and after pneumococcal conjugate vaccination in persons with HIV: brief report. Curr HIV Res. 2012;10:252-5.
38. Wolter N, Cohen C, Tempia S, Madhi SA, Venter M, Moyes J, et al. HIV and influenza virus infections are associated with increased blood pneumococcal load: a prospective, hospital-based observational study in South Africa, 2009-2011. J Infect Dis. 2013;209:46-65.
39. Klein MB, Yang H, DelBalso L, Carbonneau J, Frost E, Boivin G. Viral pathogens including human metapneumovirus are the primary cause of febrile respiratory illness in HIV-infected adults receiving antiretroviral therapy. J Infect Dis. 2010;201:297-301. The only prospective study of the role of viral respiratory pathogens in the ART era.
40. Cunha BA, Syed U, Hage JE. Respiratory syncytial virus (RSV) community-acquired pneumonia (CAP) in a hospitalized adult with human immunodeficiency virus (HIV) mimicking influenza A and Pneumocystis (carinii) jiroveci pneumonia (PCP). Heart Lung. 2012;41:76-82.
41. Gupta A, Mody P, Gupta S. A case of respiratory syncytial virus infection in an HIV-positive adult. Case Rep Infect Dis. 2012;2012:267028.
42. Sheth AN, Althoff KN, Brooks JT. Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature. Clin Infect Dis. 2011;52:219-27.
43. Cohen C, Simonsen L, Sample J, Kang JW, Miller M, Madhi SA, et al. Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America. Clin Infect Dis. 2012;55:996-1003.
44. Martínez E, Marcos MA, Hoyo-Ulloa I, Antón A, Sánchez M, Vilella A, et al. Influenza A H1N1 in HIV-infected adults. HIV Med. 2011;12:236-45.
45. Sheth AN, Patel P, Peters PJ. Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic. Curr HIV/AIDS Rep. 2011;8:181-91.
46. Cooper CL. Pandemic H1N12009 influenza and HIV: a review of natural history, management and vaccine immunogenicity. Curr Opin Infect Dis. 2012;25:26-35.
47. Assiri A, AL-Tawfiq JA, AL-Rabeeah AA, Al Rabiah FA, AlHajjar S, Al-Barrak A, et al. Epidemiological, demographic and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13:752-61.
48. Federico M. HIV-protease inhibitors block the replication of both vesicular stomatitis and influenza viruses at an early post-entry replication step. Virology. 2011;417:37-49.
49. Chew KW, Yen IH, Li JZ, Winston LG. Predictors of pneumonia severity in HIV-infected adults admitted to an urban public hospital. AIDS Patient Care STDS. 2011;25(5):273-7.
50. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64 Suppl 3:iii1-iii55.
51. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72.
52. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect. 2011;17 Suppl 6:E1-E59.
53. http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2011.03672.x/pdf.
54. Crowther-Gibson P, Cohen C, Klugman KP, de Gouveia L, von Gottberg A. Group for Enteric, Respiratory, and Meningeal Disease Surveillance in South Africa (GERMS-SA). Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008. Antimicrob Agents Chemother. 2012;56:5088-95.
55. Munier AL, de Lastours V, Varon E, Donay JL, Porcher R, Molina JM. Invasive pneumococcal disease in HIV-infected adults in France from 2000 to 2011: antimicrobial susceptibility and implication of serotypes for vaccination. Infection. 2013;41:663-8.
56. Christensen D, Feldman C, Rossi P, Marrie T, Blasi F, Luna C, et al. Community-Acquired Pneumonia Organization Investigators. HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study. Clin Infect Dis. 2005;41:554-6.
57. Bordon J, Kapoor R, Martinez C, Portela D, Duvvuri P, Klochko A, et al. CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients. Int J Infect Dis. 2011;15:e822-7. Further evidence that CD4+ cell counts do not influence outcome of community-acquired pneumonia.
58. Mor SM, Aminawung JA, Demaria Jr A, Naumova EN. Pneumonia and influenza hospitalization in HIV-positive seniors. Epidemiol Infect. 2011;139:1317-25. New data suggesting that the aging HIV-infected populations may experience worse outcomes with pneumonia.
59. Shirley DK, Kesari RK, Glesby MJ. Factors associated with smoking in HIV-infected patients and potential barriers to cessation. AIDS Patient Care STDS. 2013;27:603-12.
60. Vijayaraghavan M, Penko J, Vittinghoff E, Bangsberg DR, Miaskowski C, Kushel MB. Smoking behaviors in a community-based cohort of hiv-infected indigent adults. AIDS Behav. 2013. doi: 10.1007/s10461-013-0576-z.
61. Waweru P, Anderson R, Steel H, Venter WD, Murdoch D, Feldman C. The prevalence of smoking and the knowledge of smoking hazards and smoking cessation strategies among HIV-positive patients in Johannesburg, South Africa. S Afr Med J. 2013;103:858-60.
62. De P, Farley A, Lindson N, Aveyard P. Systematic review and meta-analysis: influence of smoking cessation on incidence of pneumonia in HIV. BMC Med. 2013;11:15. Important systematic review of the data on smoking cessation reducing pneumonia incidence in HIV-infected individuals.
63. Cui Q, Robinson L, Elston D, Smaill F, Cohen J, Quan C, et al. Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study. AIDS Patient Care STDS. 2012;26:12-9.
64. Pedersen RH, Lohse N, Østergaard L, Søgaard OS. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med. 2011;12:323-33. Review of pneumonia polysaccharide vaccination effectiveness.
65. Nielsen H, Kvinesdal B, Benfield TL, Lundgren JD, Konradsen HB. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis. 1998;30:597-601.
66. Lu CL, Hung CC, Chuang YC, Liu WC, Su CT, Su YC, et al. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy. Hum Vaccin Immunother. 2013;9(2):398-404.
67. Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother. 2012;8:161-73.
68. Slayter KL, Singer J, Lee TC, Kayhty H, Schlech WF. Immunization against pneumococcal disease in HIV-infected patients: conjugate versus polysaccharide vaccine before or after reconstitution of the immune system (CTN-147). Int J STD AIDS. 2013;24:227-31.
69. Burgos J, Peñaranda M, Payeras A, Villoslada A, Curran A, Garau M, et al. Invasive pneumococcal disease in HIV-infected adults: clinical changes after the introduction of the pneumococcal conjugate vaccine in children. J Acquir Immune Defic Syndr. 2012;59:31-8.
70. Nzenze SA, Shiri T, Nunes MC, Klugman KP, Kahn K, Twine R, et al. Temporal changes in pneumococcal colonization in a rural African community with high HIV prevalence following routine infant pneumococcal immunization. Pediatr Infect Dis J. 2013;32:1270-8.
71. Geretti AM, BHIVA Immunization Writing Committee, Brook G, Cameron C, Chadwick D, Heyderman RS, et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med. 2008;9:795-848.
72. AIDSinfo. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Rockville, MD: US Department Health and Human Services. http://aidsinfo.nih.gov/guidelines/html/4/adult-and- adolescent-oi-prevention-and-treatment-guidelines/0.
73. Rozenbaum MH, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ. 2012;345:e6879. Economic analysis of the cost-effectiveness of using PCV-13 immunization for at-risk groups including HIV-infected individuals.
74. Smith KJ, Nowalk MP, Raymund M, Zimmerman RK. Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine. 2013;31:3950-6.
75. Cho BH, Stoecker C, Link-Gelles R, Moore MR. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. 2013;31:6011-31.
76. Hunter MG, Post JJ. An audit of pneumococcal and hepatitis vaccination in an outpatient HIV clinic. Sex Health. 2012;9:495-6.
77. Beck CR, McKenzie BC, Hashim AB, Harris RC. University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012;206:1250-9.
78. McKittrick N, Frank I, Jacobson JM, White CJ, Kim D, Kappes R, et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med. 2013;158:19-26.